40 results
DEFA14A
ALKS
Alkermes plc
13 Jun 23
Additional proxy soliciting materials
7:08am
., (current), the Biotechnology Innovation Organization (“BIO”) (current), and Pharmaceutical Research and Manufacturers of America (“PhRMA”) (current
DEFA14A
4dxtg
7 Jun 23
Additional proxy soliciting materials
5:28pm
DEFC14A
6ejag
25 May 23
Proxy in contested solicitation
4:03pm
PRER14A
83veu j8fzrn6jz
19 May 23
Preliminary revised proxy
5:23pm
PREC14A
qepgw7z2m 6ww2b9
8 May 23
Preliminary proxy with contested solicitation
4:34pm
8-K
EX-99.2
unx3v78erh
2 Nov 22
Alkermes plc Reports Third Quarter 2022 Financial Results
7:06am
8-K
EX-99.3
9hfftlo7zphgwulb2
2 Nov 22
Alkermes plc Reports Third Quarter 2022 Financial Results
7:06am
DEFC14A
wt6tkn0g97jlck41zhm
6 Jun 22
Proxy in contested solicitation
5:29pm
PREC14A
b8f9f799
26 May 22
Preliminary proxy with contested solicitation
5:29pm
DEFA14A
EX-99.1
o09fxr9n
11 Jan 22
Additional proxy soliciting materials
7:02am
8-K
EX-99.1
hj4 056oz86
11 Jan 22
Regulation FD Disclosure
7:00am
8-K
EX-99.1
4ttxye8t46ixioomok
19 Nov 21
Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors
7:08am